RMD Open
inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021;80:1255–65. 16 Hua C, Barnetche T, Combe B, et al . Effect of methotrexate, anti- tumor necrosis factor α , and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 2014;66:1016–26. 17 Arad U, Tzadok S, Amir S, et al . The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011;29:1643–8. 18 Amanna IJ, Slifka MK. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology 2011;411:206–15. 19 Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis 2021;80:1357–9. 20 Mrak D, Tobudic S, Koblischke M, et al . SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis 2021;80:1345–50. 21 Prendecki M, Clarke C, Edwards H, et al . Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis 2021;80:1322–9. 22 Rondaan C, Furer V, Heijstek MW, et al . Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open 2019;5:e001035. 23 Boyarsky BJ, Werbel WA, Avery RK, et al . Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA 2021;325:1784. 24 Boyarsky BJ, Ruddy JA, Connolly CM, et al . Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021;80:1098–9. 25 Haberman RH, Herati R, Simon D, et al . Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune- mediated inflammatory disease. Ann Rheum Dis 2021;80:1339–44. 26 Mahil SK, Bechman K, Raharja A, et al . The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol 2021;3:e627–37. 27 Pinti M, Appay V, Campisi J, et al . Aging of the immune system: focus on inflammation and vaccination. Eur J Immunol 2016;46:2286–301. 28 Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol 2020;20:581–2. 29 McElhaney JE, Xie D, Hager WD, et al . T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006;176:6333–9. 30 McElhaney JE, Ewen C, Zhou X, et al . Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009;27:2418–25. 31 Juno JA, Tan H-X, Lee WS, et al . Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med 2020;26:1428–34. 32 Quinti I, Lougaris V, Milito C, et al . A possible role for B cells in COVID-19? lesson from patients with agammaglobulinemia. J Allergy Clin Immunol 2020;146:211–3. 33 Isaacs JD, Burmester GR. Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs. Ann Rheum Dis 2020;79:991–3.
and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
ORCID iD Jose G Ruiz de Morales http://orcid.org/0000-0002-0291-4071
REFERENCES 1 Landewé RBM, Machado PM, Kroon F, et al . EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020;79:851–8. 2 Akiyama S, Hamdeh S, Micic D, et al . Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis 2021;80:384–91. 3 Michelena X, Borrell H, López-Corbeto M, et al . Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 2020;50:564–70. 4 Mikuls TR, Johnson SR, Fraenkel L, et al . American College of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 2. Arthritis Rheumatol 2020;72:e1–12. 5 Strangfeld A, Schäfer M, Gianfrancesco MA, et al . Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 2021;80:930–42. 6 Fernández-Gutiérrez B, Leon L, Madrid A, et al . Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents. Ther Adv Musculoskelet Dis 2021;13:1759720X2096269–12. 7 Schulze-Koops H, Krueger K, Vallbracht I, et al . Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 2021;80:e67. 8 Regierer AC, Hasseli R, Schäfer M, et al . TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open 2021;7:e001896. 9 Graham BS. Rapid COVID-19 vaccine development. Science 2020;368:945–6. 10 Jeyanathan M, Afkhami S, Smaill F, et al . Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 2020;20:615–32. 11 Polack FP, Thomas SJ, Kitchin N, et al . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15. 12 Baden LR, El Sahly HM, Essink B, et al . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16. 13 Lopez A, Mariette X, Bachelez H, et al . Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J Autoimmun 2017;80:10–27. 14 Grifoni A, Weiskopf D, Ramirez SI, et al . Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020;181:1489–501. 15 Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with
8
Sieiro Santos C, et al . RMD Open 2022; 8 :e001898. doi:10.1136/rmdopen-2021-001898
Powered by FlippingBook